Condition: B-cell Non-Hodgkin Lymphoma (B-NHL) · Sponsor: Cellectis S.A.
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
This description comes directly from the study's public registry record.
Cellectis Central Contact · +1 917 580-1088 · clinicaltrials@cellectis.com
Always discuss trial participation with your own doctor first.
| The University of Chicago Medical Center (UCMC) | Chicago, Illinois, United States | Recruiting |
| Harvard Medical School - Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey (CINJ) - New Brunswick | New Brunswick, New Jersey, United States | Recruiting |
| Sarah Cannon - St. David South Austin Medical Center | Austin, Texas, United States | Recruiting |
| Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud | Pierre-Bénite, Auvergne Rhone Alpe, France | Recruiting |
| Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Saint-Eloi | Montpellier, Occitanie, France | Recruiting |
| Centre Hospitalier Universitaire de Nantes (CHU de Nantes)-Hotel-Dieu | Nantes, France | Recruiting |
| Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Louis - Centre Integre en Cancerologie | Paris, Île-de-France Region, France | Recruiting |
| Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona | Pamplona, Navarre, Spain | Recruiting |
| Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS) | Seville, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05607420